A further phase I trial consisting of intravenous etoposide phosphate as continuous infusion over 10 days in combination with subcutaneous GM-CSF on days 12–19 is needed to determine the MTD of etoposide phosphate with subcutaneous GM-CSF for recommendations for future phase II trials in patients with recurring ovarian cancer. Here, CSF2 is linked to ovarian carcinoma.